Survodutide vs Amycretin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: BI 456906
Survodutide is an injectable dual agonist that hits both the GLP-1 and glucagon receptors, discovered by Zealand Pharma and developed by Boehringer Ingelheim. It is being tested for obesity and for fatty liver disease (MASH), and it carries an FDA Breakthrough Therapy designation for MASH. It is still investigational and not approved for any use as of October 2026, and no US filing has been publicly announced.
Also: Zenagamtide, NNC0487-0111
Amycretin is Novo Nordisk's single-molecule agonist of both the GLP-1 and amylin receptors, developed as a once-weekly injection and a once-daily pill. Early trials produced some of the biggest weight-loss numbers seen with any obesity drug so far, and the injectable version entered phase 3 (the AMAZE program) in 2026. It is not approved anywhere, and everything known about it comes from company-run trials of up to 36 weeks.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Survodutide | Amycretin |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The drug works on two fronts at once. The GLP-1 receptor arm dampens appetite, slows how fast the stomach empties, and improves blood sugar handling, the same lever that semaglutide pulls. The glucagon receptor arm is the twist: glucagon signaling raises energy expenditure and pushes the liver to burn fat rather than store it. The idea, still being proven out in trials, is that adding controlled glucagon activity to GLP-1 action burns more energy and clears liver fat faster than a GLP-1 drug alone, which is why survodutide is aimed squarely at fatty liver disease. | Amycretin hits two appetite systems at once. The GLP-1 side slows stomach emptying, boosts insulin release after meals, and dampens appetite in the brain, the same biology behind semaglutide. The amylin side mimics a hormone your pancreas releases alongside insulin, which acts on the brainstem to make you feel full sooner and also curbs glucagon after eating. Novo combined these two signals in one molecule rather than mixing two drugs (which is what its CagriSema combination does). The bet is that the two pathways add together, giving more weight loss than either alone. That idea fits the early data, but it has not yet been tested head-to-head against semaglutide or tirzepatide in a large trial. |
| Common Dosing | Limited community data available See research protocols | Trial doses of 1.25-40 mg once weekly (injection) Once weekly (injection) or once daily (tablet) |
| Administration | Subcutaneous injection weekly | Subcutaneous injection once weekly, or oral tablet once daily (separate formulations) |
| Typical Duration | Long-term use expected | 20-36 weeks in published trials; phase 3 runs longer |
| Best Time to Take | Once weekly, same day each week | Same day each week (injection); trial protocols set timing for the tablet |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is one of the more advanced incretin dual agonists, and the human data are real, not hypothetical. In a Phase 2 MASH trial published in the New England Journal of Medicine in 2024 (Sanyal et al.), 293 biopsy-confirmed patients got weekly survodutide or placebo for 48 weeks, and MASH improved without worsening fibrosis in 47% of the 2.4 mg group and 62% of the 4.8 mg group, versus 14% on placebo. A separate Phase 2 obesity study showed weight loss up to roughly 18.7% at 46 weeks in completers. In April 2026, Boehringer Ingelheim and Zealand Pharma reported that the Phase 3 SYNCHRONIZE-1 obesity trial hit its mark with about 16.6% average weight loss, and SYNCHRONIZE-MASLD showed about 12% weight loss versus 1% on placebo plus large drops in liver fat. Large Phase 3 MASH trials (LIVERAGE and LIVERAGE-Cirrhosis) are ongoing. The catch worth knowing: nausea, vomiting, and other GI side effects are common, as with the whole incretin class, and approval is not expected before 2027. | Two early trials were published in The Lancet in June 2025. In the subcutaneous phase 1b/2a trial (125 adults with overweight or obesity), the estimated weight loss assuming full adherence was 24.3% at 60 mg over 36 weeks and 22.0% at 20 mg over 36 weeks, versus roughly flat weight on placebo, with no plateau by the end of treatment. A separate phase 1 trial of the oral tablet (144 people, 12 weeks) showed up to 13.1% loss at the highest dose. In November 2025 Novo reported a 36-week phase 2 trial in 448 adults with type 2 diabetes: up to 14.5% weight loss with weekly injections (2.6% on placebo), up to 10.1% with the daily pill, and HbA1c drops of up to 1.8 points. Side effects were mostly gastrointestinal, dose-related, and mild to moderate. Novo moved both forms into phase 3; AMAZE 1 (weekly injection at 1.25, 5, 20 or 40 mg versus placebo, about 1,150 people without diabetes) is registered as NCT07339423 with completion expected in 2029. Honest caveats: the headline numbers come from small trials using an efficacy estimand that assumes everyone stayed on drug, and long-term safety is unknown. |
Frequently Asked Questions: Survodutide vs Amycretin
What is the difference between Survodutide and Amycretin?
Survodutide is a weight loss peptide that survodutide is an injectable dual agonist that hits both the glp-1 and glucagon receptors, discovered by zealand pharma and developed by boehringer ingelheim. it is being tested for obesity and for fatty liver disease (mash), and it carries an fda breakthrough therapy designation for mash. it is still investigational and not approved for any use as of october 2026, and no us filing has been publicly announced. Amycretin is a weight loss peptide that amycretin is novo nordisk's single-molecule agonist of both the glp-1 and amylin receptors, developed as a once-weekly injection and a once-daily pill. early trials produced some of the biggest weight-loss numbers seen with any obesity drug so far, and the injectable version entered phase 3 (the amaze program) in 2026. it is not approved anywhere, and everything known about it comes from company-run trials of up to 36 weeks. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Survodutide or Amycretin?
Neither is universally "better" - the choice depends on your specific goals. Survodutide is typically used for weight loss purposes, while Amycretin is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Survodutide and Amycretin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Survodutide and Amycretin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.